- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/36 - One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
Patent holdings for IPC class C07D 239/36
Total number of patents in this class: 265
10-year publication summary
|
26
|
22
|
14
|
21
|
20
|
17
|
11
|
9
|
15
|
4
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 358 |
14 |
| Celgene Quanticel Research, Inc. | 154 |
13 |
| Takeda Pharmaceutical Company Limited | 2700 |
10 |
| Sunshine Lake Pharma Co., Ltd. | 631 |
8 |
| Merck Sharp & Dohme Corp. | 2183 |
7 |
| Neurocrine Biosciences, Inc. | 470 |
7 |
| Eonhf, Inc. | 45 |
7 |
| ASKA Pharmaceutical Co., Ltd. | 96 |
5 |
| Glenmark Pharmaceuticals S.A. | 115 |
5 |
| z Factor Limited | 13 |
5 |
| Centessa Pharmaceuticals (UK) Limited | 61 |
5 |
| Novartis AG | 10172 |
4 |
| F. Hoffmann-La Roche AG | 7792 |
4 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 879 |
4 |
| Lighthouse Pharmaceuticals, Inc. | 11 |
4 |
| Glaxo Group Limited | 4353 |
3 |
| Bristol-myers Squibb Company | 4761 |
3 |
| Hoffmann-La Roche Inc. | 3849 |
3 |
| The Regents of the University of California | 20924 |
3 |
| Merck Patent GmbH | 5755 |
3 |
| Other owners | 148 |